Get the latest Science News and Discoveries
Recent FDA committee vote could speed multiple myeloma drug approval - EurekAlert
A U.S. Food and Drug Administration committee voted unanimously last month to approve a new clinical endpoint, minimal residual disease (MRD), when evaluating proposed drugs to treat multiple myeloma. The 12-0 vote by committee members was based primarily on an analysis spearheaded by C. Ola Landgren, M.D., Ph.D., first author of a new paper published yesterday in the journal Blood.
None
Or read this on Eureka Alert